Startseite The crystal structure of the co-crystal: 2-hydroxybenzoic acid – N′-(butan-2-ylidene)pyridine-4-carbohydrazide, C10H13N3O·C7H6O3
Artikel Open Access

The crystal structure of the co-crystal: 2-hydroxybenzoic acid – N′-(butan-2-ylidene)pyridine-4-carbohydrazide, C10H13N3O·C7H6O3

  • Itumeleng B. Setshedi ORCID logo und Mark G. Smith ORCID logo EMAIL logo
Veröffentlicht/Copyright: 19. Juli 2021

Abstract

C10H13N3O·C7H6O3, monoclinic, P21/n (no. 14), a = 7.4038(9) Å, b = 30.448(3) Å, c = 7.6744(8) Å, β = 112.013(3)°, V = 1603.9(3) Å3, Z = 4, R gt (F) = 0.0492, wR ref (F 2) = 0.1384, T = 173 K.

CCDC no.: 2081948

The asymmetric unit of the title crystal structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless block
Size: 0.43 × 0.34 × 0.31 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.10 mm−1
Diffractometer, scan mode: Bruker D8 Venture Photon, ω
θ max, completeness: 28.0°, >99%
N(hkl) measured, N(hkl)unique, R int: 77005, 3868, 0.034
Criterion for I obs, N(hkl) gt: I obs > 2 σ(I obs), 3459
N(param)refined: 217
Programs: Bruker [1], SHELX [2], WinGX [3], PLATON [4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
C1 0.47422 (19) 0.69710 (4) 0.79314 (18) 0.0183 (3)
C2 0.4466 (2) 0.71769 (5) 0.6233 (2) 0.0232 (3)
H2 0.4381 0.7488 0.6132 0.028*
C3 0.4316 (2) 0.69213 (5) 0.4685 (2) 0.0262 (3)
H3 0.4147 0.7064 0.3534 0.031*
C4 0.4657 (2) 0.62846 (5) 0.6387 (2) 0.0267 (3)
H4 0.4704 0.5973 0.644 0.032*
C5 0.4857 (2) 0.65154 (5) 0.8007 (2) 0.0228 (3)
H5 0.5069 0.6364 0.915 0.027*
C6 0.5103 (2) 0.72181 (4) 0.97278 (18) 0.0188 (3)
C7 0.4555 (2) 0.82709 (5) 1.1042 (2) 0.0218 (3)
C8 0.4302 (3) 0.85230 (5) 0.9284 (2) 0.0322 (4)
H8A 0.4336 0.8839 0.9544 0.048*
H8B 0.5358 0.8448 0.886 0.048*
H8C 0.3048 0.8447 0.8302 0.048*
C9 0.4893 (2) 0.85415 (5) 1.2773 (2) 0.0267 (3)
H9A 0.3772 0.8743 1.2516 0.032*
H9B 0.6064 0.8725 1.3007 0.032*
C10 0.5164 (3) 0.82882 (6) 1.4547 (2) 0.0327 (4)
H10A 0.5372 0.8494 1.5586 0.049*
H10B 0.3998 0.8112 1.4357 0.049*
H10C 0.6297 0.8094 1.4849 0.049*
C11 0.2919 (2) 0.52453 (5) 0.0505 (2) 0.0222 (3)
C12 0.2453 (2) 0.48062 (5) 0.0713 (2) 0.0272 (3)
C13 0.1844 (2) 0.45300 (5) −0.0850 (3) 0.0344 (4)
H13 0.1503 0.4234 −0.0727 0.041*
C14 0.1737 (3) 0.46848 (6) −0.2571 (2) 0.0362 (4)
H14 0.1321 0.4493 −0.3625 0.043*
C15 0.2225 (2) 0.51151 (5) −0.2795 (2) 0.0313 (3)
H15 0.2161 0.5218 −0.3986 0.038*
C16 0.2807 (2) 0.53909 (5) −0.1255 (2) 0.0250 (3)
H16 0.3138 0.5687 −0.1398 0.03*
C17 0.3518 (2) 0.55441 (5) 0.2134 (2) 0.0248 (3)
N1 0.42658 (18) 0.76138 (4) 0.95584 (16) 0.0222 (3)
H1A 0.3544 0.7721 0.8451 0.027*
N2 0.43990 (19) 0.64817 (4) 0.47484 (18) 0.0267 (3)
N3 0.45845 (18) 0.78518 (4) 1.12194 (17) 0.0226 (3)
O1 0.61992 (16) 0.70594 (3) 1.12281 (14) 0.0255 (2)
O2 0.38141 (18) 0.59551 (3) 0.17611 (15) 0.0307 (3)
H2A 0.415 0.6104 0.2753 0.046*
O3 0.3705 (2) 0.54221 (4) 0.37140 (16) 0.0391 (3)
O4 0.2580 (2) 0.46347 (4) 0.23750 (18) 0.0404 (3)
H4A 0.2961 0.4829 0.321 0.061*

Source of material

All reagents used were commercially available and used without further purification. An amount of 0.220 g of isonicotinic acid hydrazide (1.60 mmol), 0.220 g of 2-hydroxy-benzoic acid (1.59 mmol) and 3.0 mL of 2-butanone were added into a screw-top dram vial (with rubber septum) and stirred at 300 rpm at 60 °C for 10 min. The vial was closed, and the solution was allowed to reflux in the vial at 60 °C for 24 h. The solution was then left slightly open to allow slow evaporation at room temperature. Colourless block crystals were observed after three days.

Experimental details

The collection method involved ω-scans of width 0.5°. Data reduction was carried out using SAINT–Plus version 6.02.6 software, and SADABS was used to process empirical absorption corrections [1]. The crystal structure was solved through direct methods using SHELXS-97 [2]. Hydrogen atoms were positioned geometrically and allowed to ride on their respective parent atoms with d(C—H) = 0.95 Å and U iso (H) = 1.2U eq (C). Diagrams and publication material were generated using WinGX [3] and PLATON [4].

Comment

Isoniazid, a synthetic derivative of nicotinic acid [5] is a drug that has been used for many years as a first-line anti–tuberculosis (TB) drug. However, bacterial strains targeted by isoniazid have developed resistance over the years, thus leading to the urgent need to develop novel drugs. There are several ways in which novel anti–TB drugs can be derived. However, one method that stands out is by making modifications to existing drugs so that they can no longer be deactivated by mycobacteria [6]. Therefore, the compound being reported in this article is a modification of isoniazid.

As shown in the figure, the asymmetric unit contains one molecule of N′-(butan-2-ylidene)pyridine-4-carbohydrazide and one molecule of 2-hydroxybenzoic acid (salicylic acid). All bond lengths and angles are as expected [7]. Each carbohydrazide moiety is hydrogen bonded by a O2—H2a⋯N2 hydrogen bond to a salicylic acid molecule to form a co-crystal. As is expected from similar co-crystals reported in the literature [8], this co-crystal is formed through a robust carboxylic acid ⋯ pyridine heterosynthon. The phenol group on the salicylic acid molecule forms an expected intramolecular S(6) hydrogen bond [9], between the H4a donor and the O3 acceptor. Each carbohydrazide moiety is also hydrogen bonded via its N1–H donor to the carbonyl oxygen (O1) acceptor of an adjacent carbohydrazide moiety (not shown in the figure). These hydrogen bonding interactions within the packing form a one dimensional (1D) ribbon along the a-axis. The plane of the salicylic acid is slightly offset from the plane of the pyridine ring by an acute angle of 22°. However, the pyridine rings of the carbohydrazide moiety as well as the benzene rings of salicylic acid lie parallel to each other respectively, and the packing is thus stabilized by π-stacking of these rings along the a-axis.


Corresponding author: Mark G. Smith, Chemistry Department, University of South Africa, Unisa Science Campus, 28 Pioneer Avenue Florida, Roodepoort, Gauteng, South Africa, E-mail:

Funding source: National Research Foundation 10.13039/501100001321

Award Identifier / Grant number: 117850

Award Identifier / Grant number: 118127

Acknowledgement

The authors would like to thank Prof. M. Fernandes (University of the Witwatersrand) for his assistance with crystallographic data collection.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was supported by the National Research Foundation (NRF) Thuthuka Grant Number 118127 as well as Thuthuka Grant Number 117850.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. SAINT–Plus and SADABS; Bruker AXS Inc.: Madison, WI, USA, 2004.Suche in Google Scholar

2. Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Suche in Google Scholar PubMed

3. Farrugia, L. J. WinGX suite for small-molecule single-crystal crystallography. J. Appl. Crystallogr. 1999, 32, 837–838; https://doi.org/10.1107/s0021889899006020.Suche in Google Scholar

4. Spek, A. L. Structure validation in chemical crystallography. Acta Crystallogr. 2009, D65, 148–155; https://doi.org/10.1107/s090744490804362x.Suche in Google Scholar

5. Pubchem. Isoniazid open chemistry database. 2018, 1–75. https://pubchem.ncbi.nml.nih.gov/compound/isoniazid#section=Top.Suche in Google Scholar

6. Hu, Y.-Q., Zhang, S., Zhao, F., Gao, C., Feng, L.-S., Lv, Z.-S. Isoniazid derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 2017, 133, 255–267; https://doi.org/10.1016/j.ejmech.2017.04.002.Suche in Google Scholar PubMed

7. Lemmerer, A., Bernstein, J., Kahlenberg, V. One-pot covalent and supramolecular synthesis of pharmaceutical co-crystals using the API isoniazid: a potential supramolecular reagent. CrystEngComm 2010, 12, 2856–2864; https://doi.org/10.1039/c000473a.Suche in Google Scholar

8. Aakoroy, C. B., Hussain, I., Forbes, S., Desper, J. Exploring the hydrogen-bond preference of N–H moieties in co-crystals assembled via O–H(acid)⃛N(py) intermolecular intereactions. CrystEngComm 2007, 9, 46–54.10.1039/B614984GSuche in Google Scholar

9. Bernstein, J., Davis, R. E., Shimoni, L., Chang, N. L. Patterns in hydrogen bonding: functionality and graph set analysis in crystals. Angew. Chem. Int. Ed. 1995, 34, 1555–1573; https://doi.org/10.1002/anie.199515551.Suche in Google Scholar

Received: 2021-06-03
Accepted: 2021-06-30
Published Online: 2021-07-19
Published in Print: 2021-09-27

© 2021 Itumeleng B. Setshedi and Mark G. Smith, published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of [aqua-(4-iodopyridine-2,6-dicarboxylato-κ3 O,N,O′)-(1,10-phenanothroline-κ2 N,N′)copper(II)] dihydrate, C19H16O7N3CuI
  4. The crystal structure of tetrakis(1-isopropyl-1H-imidazolium) octamolybdate, C24H44Mo8N8O26
  5. Crystal structure of catena-poly[bis(µ2-3,5-bis(1-imidazolyl)pyridine-κ2 N:N′)-(µ2-3-nitrophthalato-k3 O,O′:O″)cadmium(II)] dihydrate, C30H25N11O8Cd
  6. The crystal structure of diaqua-bis(2-(3-(1H-pyrazol-4-yl)-1H-1,2,4-triazol-5-yl)pyridine-κ2 N:N′)-bis(3,5-dicarboxybenzoato-κ1 O)cobalt(II), C38H30CoN12O14
  7. Crystal structure of the nickel(II) complex aqua-(2,6-di(pyrazin-2-yl)-4,4′-bipyridine-κ3 N,N′,N′′)-(phthalato-κ2 O,O′)nickel(II) tetrahydrate, C26H26N6O9Ni
  8. The crystal structure of 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminium 3-carboxyprop-2-enoate, C21H20FN3O6S
  9. The crystal structure of 1,2-bis(4-pyridyl)ethane - 4,4-dihydroxydiphenylmethane (1/1), C25H21N2O2
  10. Crystal structure of bis(2-((E)-5-chloro-2-hydroxybenzylidene)hydrazineyl)methaniminium trifluoroacetate dihydrate, C34H36Cl4N10O12
  11. Crystal structure of 1-cyclopropyl-7-ethoxy-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, C15H13F2NO4
  12. Crystal structure of methyl 3-(1H-naphtho[1,8-de][1,3,2]diazaborinin-2(3H)-yl)benzoate, C18H15BN2O2
  13. Crystal structure of (E)-N′-(2-chloro-6-hydroxybenzylidene)-2-hydroxybenzohydrazide, C14H11ClN2O3
  14. Crystal structure of Al-rich fluorophlogopite, K1.0(Mg2.8Al0.2)(Si2.8Al1.2)O10F2
  15. The crystal structure of 4,5-diiodo-1,3-dimesityl-1H-1,2,3-triazol-3-ium hexafluoridoantimonate(V), C20H22F6I2N3Sb
  16. Crystal structure of tris(3-iodopyridin-1-ium) catena-poly[(hexachlorido-κ1 Cl)-(μ2-trichlorido-κ2 Cl:Cl)diantimony(III)], C15H15Cl9I3N3Sb2
  17. Crystal structure of methyl 2-(1H-naphtho[1,8-de][1.3.2]diazaborinin-2(3H-yl)benzoate C18H15BN2O2
  18. The crystal structure of 1,8-bis(4-methoxybenzoyl)naphthalene-2,7-diyl dibenzoate, C40H28O8
  19. Crystal structure of 2-bromo-1,3,6,8-tetramethylBOPHY (BOPHY = bis(difluoroboron)-1,2-bis((1H-pyrrol-2-yl)methylene)hydrazine), C14H15B2BrF4N4
  20. The crystal structure of (E)-3-chloro-2-(2-(2-fluorobenzylidene)hydrazinyl)pyridine, C12H9ClFN3
  21. Crystal structure of bis(µ2- 4-iodopyridine-2,6-dicarboxylato-κ3O:N:O′)-bis(4-iodopyridine-2,6-dicarboxylato-κ3O:N:O′)-bis(µ2-1-(4-pyridyl)piperazine-κ2N:N′)-hexa-aqua-tetra-copper(II), C46H46Cu4I4N10O22
  22. Crystal structure of poly[diaqua-(μ2-2,5-dihydroxyterephthalato-κ2O:O′)(μ2-bis(4-pyridylformyl)piperazine-κ2N:N′)cadmium(II)] dihydrate, C24H28CdN4O12
  23. Crystal structure of poly[aqua-(μ2-1,3-di(1H-imidazol-1-yl)propane-κ2N:N′)-(μ3-2,3,5,6-tetrafluoroterephthalato-κ3O:O′:O′′)cadmium(II)], C17H14N4O5F4Cd
  24. Crystal structure of 6-(quinolin-8-yl)benzo[a]phenanthridin-5(6H)-one, C26H16N2O
  25. The crystal structure of aqua-bis(6-chloropicolinato-κ2N,O)copper(II), C12H8Cl2N2O5Cu
  26. Crystal structure of catena-poly[diaqua-bis(μ2-4,4′-bipyridyl-κ2N:N′) disilver(I)] 4-oxidopyridine-3-sulfonate trihydrate, C25H29Ag2N5O9S
  27. The crystal structure of 4-(3-bromophenyl)pyrimidin-2-amine, C10H8BrN3
  28. Crystal structure of 6-oxo-4-phenyl-1-propyl-1,6-dihydropyridine-3-carbonitrile, C15H14N2O
  29. Crystal structure of 4-(2,2-difluoroethyl)-2,4-dimethyl-6-(trifluoromethyl)isoquinoline-1,3(2H,4H)-dione, C14H12F5NO2
  30. Crystal structure of dibromido-(1-methyl-1H-imidazole-κ1N)-(3-(3-methyl-1H-imidazol-3-ium-1-yl)propanoato-κ1O)zinc(II), C11H16Br2N4O2Zn
  31. The crystal structure of 1,1′-(((2 (dimethylamino)ethyl)azanediyl)bis(methylene)) bis(naphthalen-2-olato-κ4 N,N′,O,O′)-(pyridine-2,6-dicarboxylato-N,O,O′)- titanium(IV) ─ dichloromethane (2/1), C33H29N3O6Ti
  32. The layered crystal structure of bis(theophyllinium) hexachloridostannate (IV), C14H18N8O8SnCl6
  33. The crystal structre of 3-(1-ethenyl-1H-imidazol-3-ium-3-yl)propane-1-sulfonate, C8H12N2O3S
  34. Synthesis and crystal structure of di-tert-butyl 1″-acetyl-2,2″,9′-trioxo-4a′,9a′-dihydro-1′H,3′H,9′H-dispiro[indoline-3,2′-xanthene-4′,3″-indoline]-1,3′-dicarboxylate, C39H38N2O9
  35. The crystal structure of 4-chloro-2-(quinolin-8-yl)isoindoline-1,3-dione, C17H9ClN2O2
  36. The crystal structure of 1-fluoro-4-(p-tolylethynyl)benzene, C15H11F
  37. The crystal structure of bis[4-bromo-2-(1H-pyrazol-3-yl) phenolato-κ2N,O] copper(II), C18H12Br2CuN4O2
  38. The crystal structure of poly[(μ 3-imidazolato-κ 3 N:N:N′)(tetrahydrofuran- κ 1 O)lithium(I)], C7H11LiN2O
  39. Crystal structure of N′,N′′′-((1E,1′E)-(propane-2,2-diylbis(1H-pyrrole-5,2diyl))bis(methaneylylidene))di(nicotinohydrazide) pentahydrate, C25H24N8O2·5H2O
  40. Crystal structure of 3-(2-ethoxy-2-oxoethyl)-1-ethyl-1H-imidazol-3-ium hexafluoridophos-phate(V), C9H15F6N2O2P
  41. Crystal structure of (1,10-phenanthroline-κ2N,N′)-bis(3-thiophenecarboxylato-κ2O,O′)copper(II), C22H14N2O4S2Cu
  42. The crystal structure of 2-amino-3-carboxypyridin-1-ium iodide hemihydrate, C6H8IN2O2.5
  43. Crystal structure of (E)-7-methoxy-2-((6-methoxypyridin-2-yl)methylene)-tetralone, C18H17NO3
  44. The crystal structure of [μ-hydroxido-bis[(5,5′-dimethyl-2,2′-bipyridine-κ2N,N′)-tricarbonylrhenium(I)] bromide hemihydrate, C30H26N4O9Re2Br
  45. The crystal structure of 2,5-bis(3,5-dimethylphenyl)thiazolo[5,4-d]thiazole, C20H18N2S2
  46. The crystal structure of 5-benzoyl-1-[(E)-(4-fluorobenzylidene)amino]-4-phenylpyrimidin-2(1H)-one, C24H16FN3O2
  47. Crystal structure of monocarbonyl(N-nitroso-N-oxido-phenylamine-κ 2 O,O′)(tricyclohexylphosphine-κP)rhodium(I), C25H39N2O3PRh
  48. Crystal structure of poly[bis[μ3-1,3,5-tris[(1H-imidazol-1-yl)methyl]benzene-κ3N:N′:N″]nickel(II)] hexafluorosilicate, C36H36N12NiSiF6
  49. The crystal structure of 13-(pyrazole-1-yl-4-carbonitrile)-matrine, C19H25N5O
  50. Crystal structure of 3,5-bis((E)-4-methoxy-2-(trifluoromethyl)benzylidene)-1-methylpiperidin-4-one, C24H21F6NO3
  51. The crystal structure of N,N′-(Disulfanediyldi-2,1-phenylene)di(6′-methylpyridine)-2-carboxamide, C26H22N4O2S2
  52. Crystal structure of (E)-7-fluoro-2-(4-methoxy-2-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2
  53. Crystal structure of ethyl 1-(4-fluorophenyl)-4-phenyl-1H-pyrrole-3-carboxylate, C19H16FNO2
  54. The crystal structure of cis-diaqua-bis (N-butyl-N-(pyridin-2-yl)pyridin-2-amine-κ2N,N′)cobalt(II)] dichloride trihydrate, C28H44Cl2N6O5Co
  55. Crystal structure of (E)-7-methoxy-2-((6-methoxypyridin-3-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C18H17NO3
  56. Crystal structure of (E)-2-((3-fluoropyridin-4-yl)methylene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C17H14FNO2
  57. The crystal structure of 6-bromohexanoic acid, C6H11BrO2
  58. The crystal structure of 4-chloro-thiophenol, C6H5ClS
  59. The crystal structure of 4-bromobenzyl chloride, C7H6BrCl
  60. The crystal structure of di-tert-butyl dicarbonate, C10H18O5
  61. The crystal structure of (2-(4-chlorophenyl)-5-methyl-1,3-dioxan-5-yl)methanol, C12H15ClO3
  62. The crystal structure of the co-crystal: 2-hydroxybenzoic acid – N′-(butan-2-ylidene)pyridine-4-carbohydrazide, C10H13N3O·C7H6O3
  63. Crystal structure and anti-inflammatory activity of (E)-7-fluoro-2-((5-methoxypyridin-3-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C17H14FNO2
  64. Crystal structure of (E)-7-fluoro-2-((6-methoxypyridin-3-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C17H14FNO2
  65. Crystal structure of 1,1′-(butane-1,4-diyl)bis(3-propyl-1H-imidazol-3-ium) bis(hexafluoridophosphate), C32H56F24N8P4
  66. The crystal structure of dichlorido-bis(3-methyl-3-imidazolium-1-ylpropionato-κ2)-cadmium(II), C14H20CdCl2N4O4
  67. Crystal structure of 1-(2-cyanobenzyl)-3-cyano-4-phenyl-4-(2-cyanobenzyl)-1,4-dihydropyridine monohydrate, C56H42N8O
  68. The crystal structure of 3-(carboxymethyl)-1-ethenyl-1H-imidazol-3-ium chloride, C7H9N2O2Cl
  69. The crystal structure of adamantylmethoxydiphenylsilane, C23H28OSi
  70. Redetermination of the crystal structure of (2E,4Z,13E,15Z)-3,5,14,16-tetramethyl-2,6,13,17-tetraazatricyclo[16.4.0.07,12]docosa-1(22),2,4,7,9,11,13,15,18,20-decaene, C22H24N4
  71. Crystal structure of (E)-7-hydroxy-2-((6-methoxypyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C17H15NO3
  72. Crystal structure of catena-poly[diaqua-bis(μ2-1,3-di(1H-imidazol-1-yl)propane-κ2 N:N′)cobalt(II)] dinitrate, C18H28N10O8Co
Heruntergeladen am 15.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2021-0232/html
Button zum nach oben scrollen